Insulin glargine, a long-acting form of insulin, was marketed under the brand name LANTUS. Lantus is indicated for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. The primary activity of insulin glargine is regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. The off-label use of insulin glargine is the treatment type 2 diabetes in children and the treatment of gestational diabetes.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P06213 Gene ID: 3643.0 Gene Symbol: INSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18585815 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LANTUS Approved UseLANTUS is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Launch Date9.5610241E11 |
|||
Primary | LANTUS Approved UseLANTUS is indicated for once-daily subcutaneous administration at bedtime in the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Launch Date9.5601597E11 |
Substance Class |
Protein
Created
by
admin
on
Edited
Fri Jun 25 21:06:15 UTC 2021
by
admin
on
Fri Jun 25 21:06:15 UTC 2021
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
2ZM8CX04RZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175453
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
||
|
WHO-ATC |
A10AE54
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
||
|
NDF-RT |
N0000004931
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
||
|
NDF-RT |
N0000004931
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
||
|
WHO-ATC |
A10AE04
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
||
|
NDF-RT |
N0000004931
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
||
|
WHO-VATC |
QA10AE04
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C106526
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
160337-95-1
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
INSULIN GLARGINE
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
SUB08196MIG
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
2ZM8CX04RZ
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
7572
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
7548
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
160337-95-1
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
274783
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | RxNorm | ||
|
4901
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
CHEMBL1201497
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
M6297
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | Merck Index | ||
|
118984454
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
C47564
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
DB00047
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | |||
|
1342059
Created by
admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
|
PRIMARY | USP-RS |
From | To |
---|---|
1_7 | 2_7 |
1_19 | 2_20 |
2_6 | 2_11 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BIOSIMILAR -> PARENT | |||
|
TARGET -> AGONIST | |||
|
SUB_CONCEPT->SUBSTANCE | |||
|
BIOSIMILAR -> PARENT | |||
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|